Sugammadex ED90 dose to reverse the rocuronium neuromuscular blockade in obese patients
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | SILVA, MAURO PRADO DA | |
dc.contributor.author | MATSUI, CHRISTIANO | |
dc.contributor.author | KIM, DANIEL DONGIOU | |
dc.contributor.author | VIEIRA, JOAQUIM EDSON | |
dc.contributor.author | MALHEIROS, CARLOS ALBERTO | |
dc.contributor.author | MATHIAS, LIGIA ANDRADE SILVA TELLES | |
dc.date.accessioned | 2017-08-01T15:14:32Z | |
dc.date.available | 2017-08-01T15:14:32Z | |
dc.date.issued | 2017 | |
dc.description.abstract | ABSTRACT Objective: to determine the ED90 (minimum effective dose in 90% of patients) of sugammadex for the reversal of rocuronium-induced moderate neuromuscular blockade (NMB) in patients with grade III obesity undergoing bariatric surgery. Methods: we conducted a prospective study with the biased coin up-and-down sequential design. We chosen the following doses: 2.0mg/Kg, 2.2mg/Kg, 2.4mg/Kg, 2.6mg/Kg, 2.8mg/Kg. The complete reversal of rocuronium-induced NMB considered a T4/T1 ratio ≥0.9 as measured by TOF. After induction of general anesthesia and calibration of the peripheral nerve stimulator and accelerometer, we injected rocuronium 0.6mg/kg. We administered propofol and remifentanil by continuous infusion, and intermittent boluses of rocuronium throughout the procedure. Results: we evaluated 31 patients, of whom 26 had displayed successful reversal of the NMB with sugammadex, and failure in five. The mean time to complete moderate NMB reversal was 213 seconds (172-300, median 25-75%). The ED90 of sugammadex calculated by regression was 2.39mg/kg, with a 95% confidence interval of 2.27-2.46 mg/kg. Conclusion: the ED90 of sugammadex in patients with grade III obesity or higher was 2.39mg/kg. | |
dc.description.abstract | RESUMO Objetivos: determinar a ED90 (dose mínima eficaz em 90% dos pacientes) de sugamadex para a reversão de bloqueio neuromuscular (BNM) moderado induzido pelo rocurônio em pacientes com obesidade grau III submetidos à cirurgia bariátrica. Métodos: estudo prospectivo com o método de projeção sequencial para cima e para baixo da moeda enviesada. As seguintes doses foram escolhidas: 2,0mg/kg-1, 2,2mg/kg-1, 2,4mg/kg-1, 2,6mg/kg-1, 2,8mg/kg-1. A reversão completa de BNM induzido por rocurônio considerou uma relação T4/T1 ≥0,9 na medida do TOF. Após a indução da anestesia geral e calibração do estimulador de nervo periférico e acelerômetro, rocurônio 0,6mg/kg-1 foi injetado. Infusão contínua de propofol e remifentanil, e bolus intermitente de rocurônio foram injetados durante todo o procedimento. Resultados: trinta e um pacientes foram avaliados, 26 dos quais bem-sucedidos e cinco sem reversão completa do BNM moderado promovido pelo sugamadex. O tempo médio para completar reversão de BNM foi 213 segundos (172 a 300 segundos; mediana, 25-75%). O ED90 de sugamadex calculado pela regressão foi de 2,39mg/kg-1 com um intervalo de confiança de 95% (2,27 a 2,46mg/kg-1). Conclusão: o ED90 de sugamadex em pacientes com obesidade grau III ou superior foi 2,39mg/kg-1. | |
dc.description.index | MEDLINE | |
dc.identifier.citation | REVISTA DO COLéGIO BRASILEIRO DE CIRURGIõES, v.44, n.1, p.41-45, 2017 | |
dc.identifier.doi | 10.1590/0100-69912017001010 | |
dc.identifier.issn | 1809-4546 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/21124 | |
dc.language.iso | eng | |
dc.publisher | Colégio Brasileiro de Cirurgiões | |
dc.relation.ispartof | Revista do Colégio Brasileiro de Cirurgiões | |
dc.rights | openAccess | |
dc.rights.holder | Copyright Colégio Brasileiro de Cirurgiões | |
dc.subject | Dose-Response Relationship | |
dc.subject | Drug. Obesity. Cyclodextrins | |
dc.subject | Obesidade | |
dc.subject | Ciclodextrinas | |
dc.subject | Relação Dose-Resposta a Droga | |
dc.subject.wos | Surgery | |
dc.title | Sugammadex ED90 dose to reverse the rocuronium neuromuscular blockade in obese patients | |
dc.title.alternative | Dose ED90 de Sugamadex para reverter o bloqueio neuromuscular com rocurônio em pacientes obesos | |
dc.type | article | |
dc.type.category | original article | |
dc.type.version | publishedVersion | |
dspace.entity.type | Publication | |
hcfmusp.author.external | SILVA, MAURO PRADO DA:Brotherhood of the Santa Casa de Misericórdia de São Paulo, Brazil | |
hcfmusp.author.external | MATSUI, CHRISTIANO:Brotherhood of the Santa Casa de Misericórdia de São Paulo, Brazil | |
hcfmusp.author.external | KIM, DANIEL DONGIOU:Brotherhood of the Santa Casa de Misericórdia de São Paulo, Brazil | |
hcfmusp.author.external | MALHEIROS, CARLOS ALBERTO:Brotherhood of the Santa Casa de Misericórdia de São Paulo, Brazil | |
hcfmusp.author.external | MATHIAS, LIGIA ANDRADE SILVA TELLES:Brotherhood of the Santa Casa de Misericórdia de São Paulo, Brazil | |
hcfmusp.citation.scopus | 1 | |
hcfmusp.contributor.author-fmusphc | JOAQUIM EDSON VIEIRA | |
hcfmusp.description.beginpage | 41 | |
hcfmusp.description.endpage | 45 | |
hcfmusp.description.issue | 1 | |
hcfmusp.description.volume | 44 | |
hcfmusp.origem | sciELO | |
hcfmusp.origem.pubmed | 28489210 | |
hcfmusp.origem.scielo | SCIELO:S0100-69912017000100041 | |
hcfmusp.origem.scopus | 2-s2.0-85019006826 | |
hcfmusp.relation.reference | ABERNETHY DR, 1984, CLIN PHARMACOKINET, V9, P177 | |
hcfmusp.relation.reference | Alvarez A, 2010, Morbid Obesity: Peri-operative Management, P100 | |
hcfmusp.relation.reference | BLOUIN RA, 1987, CLIN PHARMACY, V6, P706 | |
hcfmusp.relation.reference | de Boer HD, 2007, ANESTHESIOLOGY, V107, P239, DOI 10.1097/01.anes.0000270722.95764.37 | |
hcfmusp.relation.reference | De Baerdemaeker L, 2004, CONTIN ED ANAESTH CR, V4, P152, DOI 10.1093/BJACEACCP/MKH042 | |
hcfmusp.relation.reference | Demirkaya M, 2012, J CLIN ANESTH, V24, P392, DOI 10.1016/j.jclinane.2011.11.006 | |
hcfmusp.relation.reference | DIXON WJ, 1948, J AM STAT ASSOC, V43, P109, DOI 10.2307/2280071 | |
hcfmusp.relation.reference | Donati F, 2008, EXPERT OPIN PHARMACO, V9, P1375, DOI [10.1517/14656566.9.8.1375 , 10.1517/14656560802046211] | |
hcfmusp.relation.reference | Duffull SB, 2004, CLIN PHARMACOKINET, V43, P1167, DOI 10.2165/00003088-200443150-00007 | |
hcfmusp.relation.reference | Epemolu O, 2003, ANESTHESIOLOGY, V99, P632, DOI 10.1097/00000542-200309000-00018 | |
hcfmusp.relation.reference | Garrett-Mayer E, 2006, CLIN TRIALS, V3, P57, DOI 10.1191/1740774506cn134oa | |
hcfmusp.relation.reference | George RB, 2010, CAN J ANAESTH, V57, P578, DOI 10.1007/s12630-010-9297-1 | |
hcfmusp.relation.reference | Hammer GB, 2001, PAEDIATR ANAESTH, V11, P549, DOI 10.1046/j.1460-9592.2001.00731.x | |
hcfmusp.relation.reference | Hennebry MC, 2009, BRIT J ANAESTH, V102, P806, DOI 10.1093/bja/aep095 | |
hcfmusp.relation.reference | Janmahasatian S, 2005, CLIN PHARMACOKINET, V44, P1051, DOI 10.2165/00003088-200544100-00004 | |
hcfmusp.relation.reference | Kodaka M, 2006, J CLIN ANESTH, V18, P486, DOI 10.1016/j.jclinane.2006.08.004 | |
hcfmusp.relation.reference | Llaurado S, 2012, ANESTHESIOLOGY, V117, P93, DOI 10.1097/ALN.0b013e3182580409 | |
hcfmusp.relation.reference | Loupec T, 2016, ANAESTHESIA, V71, P265, DOI 10.1111/anae.13344 | |
hcfmusp.relation.reference | MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098 | |
hcfmusp.relation.reference | Nicholson WT, 2007, PHARMACOTHERAPY, V27, P1181, DOI 10.1592/phco.27.8.1181 | |
hcfmusp.relation.reference | Pace NL, 2007, ANESTHESIOLOGY, V107, P144, DOI 10.1097/01.anes.0000267514.42592.2a | |
hcfmusp.relation.reference | Pai MP, 2000, ANN PHARMACOTHER, V34, P1066, DOI 10.1345/aph.19381 | |
hcfmusp.relation.reference | Renes SH, 2010, REGION ANESTH PAIN M, V35, P529, DOI 10.1097/AAP.0b013e3181fa1190 | |
hcfmusp.relation.reference | Sanfilippo Maria, 2013, Anesthesiol Res Pract, V2013, P389782, DOI 10.1155/2013/389782 | |
hcfmusp.relation.reference | Sorgenfrei IF, 2006, ANESTHESIOLOGY, V104, P667, DOI 10.1097/00000542-200604000-00009 | |
hcfmusp.relation.reference | Stylianou M, 2003, STAT MED, V22, P535, DOI 10.1002/sim.1351 | |
hcfmusp.relation.reference | Stylianou M, 2002, BIOMETRICS, V58, P171, DOI 10.1111/j.0006-341X.2002.00171.x | |
hcfmusp.relation.reference | Tran DQH, 2011, REGION ANESTH PAIN M, V36, P466, DOI 10.1097/AAP.0b013e3182289f59 | |
hcfmusp.relation.reference | Van Lancker P, 2011, ANAESTHESIA, V66, P721, DOI 10.1111/j.1365-2044.2011.06782.x | |
hcfmusp.relation.reference | 1983, Stat Bull Metrop Life Found, V64, P3 | |
hcfmusp.scopus.lastupdate | 2024-05-17 | |
relation.isAuthorOfPublication | 3ca0ac24-d3f4-41d9-accc-91720d431162 | |
relation.isAuthorOfPublication.latestForDiscovery | 3ca0ac24-d3f4-41d9-accc-91720d431162 |
Arquivos
Pacote Original
1 - 2 de 2
Carregando...
- Nome:
- art_SILVA_Sugammadex_ED90_dose_to_reverse_the_rocuronium_neuromuscular_2017_eng.PDF
- Tamanho:
- 195.54 KB
- Formato:
- Adobe Portable Document Format
- Descrição:
- publishedVersion (English)
Carregando...
- Nome:
- art_SILVA_Sugammadex_ED90_dose_to_reverse_the_rocuronium_neuromuscular_2017_por.PDF
- Tamanho:
- 201.88 KB
- Formato:
- Adobe Portable Document Format
- Descrição:
- publishedVersion (Portuguese)